Outcomes over the first two years of treatment with mepolizumab in severe asthma.

Elsey, Lynn; Pantin, Thomas; Holmes, Leanne-Jo; Tavernier, Gael; Fowler, Stephen J

Elsey, Lynn; Pantin, Thomas; Holmes, Leanne-Jo; Tavernier, Gael; Fowler, Stephen J.

Afiliação

Elsey L; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK lynn.elsey@mft.nhs.uk.
Pantin T; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Holmes LJ; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Tavernier G; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Fowler SJ; Faculty of Biology, School of Biological Sciences, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

Eur Respir J ; 58(6)2021 12.

Article em En | MEDLINE | ID: mdl-34711539

Assuntos

Antiasmáticos; Asma; Antiasmáticos/uso terapêutico; Anticorpos Monoclonais Humanizados/uso terapêutico; Asma/tratamento farmacológico; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos Limite: Humans Idioma: En Revista: Eur Respir J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google